Clinical trials: Antipsychotic
Frontotemporal Lobar Degeneration
Treatment Study of Frontotemporal Dementia
Objectives. The proposed clinical study has two goals: First, to assess the efficacy of a central nervous system stimulant and an atypical antipsychotic in treating the behavioral symptoms of FTD and second, to further…
- Trial name
- NCT00088751
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Metabolic Syndrome, Schizophrenia
A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
258 patients who have been treated for at least 3 months with oral olanzapine, risperidone or quetiapine in the treatment of schizophrenia and currently presenting with metabolic syndrome, will be randomized to: i) aripiprazole…
- Trial name
- NCT00508157
- Testing
- Aripiprazole, Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
- Where
- 30 sites in Belgium, Czechia and 7 more
- Volunteers
- 125 people
- Sponsor
- Bristol-Myers Squibb
Off-label Use of Atypical Antipsychotic Drugs
iADAPT: Off Label Use of Antipsychotics in the Nursing Home
The investigators propose to evaluate the effectiveness of 3 different methods to promote the dissemination and adoption of evidenced-based review guides into the nursing home setting.
- Trial name
- NCT01347619
- Testing
- Toolkit only with Web Access to Online Version, Toolkit, Periodic Audit/Feedback, Educational Messages, Items in Arm 2 plus Academic Detailing Program
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia, Schizoaffective Disorder
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.
- Trial name
- PROACTIVE (NCT00330863)
- Testing
- Risperidone microspheres, Risperidone, Olanzapine
- Where
- 8 sites in United States
- Volunteers
- 357 people
- Sponsor
- Northwell Health
Schizophrenia, Antipsychotics
The Study of Atypical Antipsychotics-induced Metabolic Disturbances
Schizophrenia is one of the most severe mental illnesses. The antipsychotic drugs, introduced in early 1950s, have revolutionized the treatment of schizophrenia.
- Trial name
- NCT00937755
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Medical University Hospital
Schizophrenia
Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia
Schizophrenia affects cognition, emotion, and behavior. Neuropsychological assessment enables a better understanding of antipsychotic effectiveness and the brain processes, underlying cognitive functioning in schizophrenia.
- Trial name
- NCT00789906
- Where
- Israel
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- BeerYaakov Mental Health Center
Schizophrenia, Schizoaffective Disorder
Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients
Background: In this proposed study, we aim to investigate safety and efficacy of two synthetic retinoids - bexarotene (Targretin; LGD1069; 4-[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl] benzoic acid) and…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Cognition
- Trial name
- NCT00534898
- Testing
- Bexarotene, Fenretinide
- Where
- Israel
- Sponsor
- Beersheva Mental Health Center
Schizophrenia, Schizoaffective Disorder
Conversion to Antipsychotic Monotherapy
This is a 12-week, with a 32-week follow-up, rater-blind, randomized controlled trial to determine whether patients with chronic schizophrenia or schizoaffective disorder receiving two different antipsychotics simultaneously will…
- Trial name
- MOPE (NCT01368458)
- Testing
- Conversion to Antipsychotic Monotherapy
- Volunteers
- 24 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs
The investigators will investigate 1. the relationships between oxidative stress-, apoptosis-related markers, mitochondria DNA copy numbers and the clinical psychopathology of schizophrenia, including severity of positive and…
- Trial name
- NCT01479413
- Where
- Taiwan
- Volunteers
- 77 people
- Sponsor
- Chang Gung Memorial Hospital
Metabolic Syndrome X
Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome
The investigators developed an easy identification model to identify metabolic syndrome in patients with schizophrenia or schizoaffective disorder who received treatment of clozapine, olanzapine, or risperidone.
- Trial name
- NCT00956189
- Testing
- amisulpride, aripiprazole
- Where
- 3 sites in Taiwan
- Volunteers
- 132 people
- Sponsor
- National Taiwan University Hospital
Anorexia Nervosa
A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa
The aim of this pilot study is to determine the safety and efficacy of risperidone for the treatment of anorexia nervosa. Hypothesis 1: Subjects on risperidone will show a more significant decrease in body image distortion and…
- Trial name
- NCT00140426
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Colorado, Denver
Schizophrenia
Antipsychotic Medication Extended Dosing Study
In patients stabilized on their antipsychotic and demonstrating evidence of good clinical response, there will not be a significant change in symptoms if their medication is decreased to every 2 days rather than daily.
- Trial name
- NCT00431574
- Testing
- dosing
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Naltrexone for Antipsychotic-Induced Weight Gain
This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NTX (NCT01866098)
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Yale University
Schizophrenia
Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia
The primary objective of this Non- Interventional Study (NIS) is to describe the use of atypical antipsychotics in subjects with Schizophrenia during the hospitalisation due to acute psychotic episode by evaluation of drug, dose…
- Trial name
- RECONNECT-S (NCT01544608)
- Where
- 7 sites in Egypt, Saudi Arabia and 1 more
- Volunteers
- 1,076 people
- Sponsor
- AstraZeneca
Schizophrenia
A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations
The purpose of this study is to compare the bioavailability of 2 extended release paliperidone pellet formulations under fasting and fed conditions with a 2 mg paliperidone oral solution under fasting conditions.
- Trial name
- NCT00796640
- Testing
- ER Paliperidone
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Intellectual Disability, Developmental Disability
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease.
- Conditions
- Intellectual Disability, Developmental Disability, Obesity
- Trial name
- METIDD (NCT05744479)
- Testing
- Metformin, Lifestyle Intervention
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Centre for Addiction and Mental Health
Colon Cancer Stage III
Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer
chlorpromazine displays a series of remarkable bio-molecular effects in cancer cells, as inhibition of cell growth, nuclear aberrations, inhibition of the phosphoinositide 3-kinase/mammilian target of rapamycin (PI3K/mTOR) axis…
- Trial name
- NCT05433402
- Testing
- ChlorproMAZINE 50 MG, Control
- Where
- Egypt
- Sponsor
- Sadat City University
Schizophrenia
Long-Term Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626872
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 254 people
- Sponsor
- Tanabe Pharma Corporation
Cocaine-Related Disorders, Substance-Related Disorders
Quetiapine for Cocaine Use and Cravings
The purpose of this study was to collect pilot data on whether quetiapine may be effective in the reduction of cocaine use and cravings in cocaine dependent individuals.
- Trial name
- NCT00232336
- Testing
- quetiapine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Schizophrenia
Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward
The purpose of this study is to compare the efficacy and tolerability of zotepine versus Risperidone in aggressive schizophrenic patients.
- Trial name
- NCT00418873
- Testing
- Zotepine, Risperidone
- Where
- 4 sites in Taiwan
- Volunteers
- 39 people
- Sponsor
- Astellas Pharma Inc